Furthermore, melanoma tumors often develop drug resistance to BRAF (V600E) inhibitors by expressing a shorter isoform of mutated BRAF that lacks the RAS binding domain and allows BRAF (V600E) proteins to dimerize and signal in a RAS independent manner11,12. This evidence concerns the gene BRAF and melanoma.